Kjøpe Abstral Sublingual 100 MG For Salg

Abstral Sublingual 100MG

Abstral Sublingual 100 MG , 200 mikrogram, 300 mikrogram, 400 mikrogram, 600 mikrogram, 800 mikrogram tabletter sublingual

Hver sublingual tablett inneholder:

100 mikrogram fentanyl (som sitrat)

200 mikrogram fentanyl (som sitrat)

300 mikrogram fentanyl (som sitrat)

400 mikrogram fentanyl (som sitrat)

600 mikrogram fentanyl (som sitrat)

800 mikrogram fentanyl (som sitrat)

For fullstendig liste over hjelpestoffer, se avsnitt 6.1.

Sublingual nettbrett

100 mikrogram sublingual tablet er en hvit, rund tablett

200 mikrogram sublingual tablet er en hvit oval tablett

300 mikrogram sublingual tablet er en hvit trekant-formet nettbrett

400 microgram sublingual tablet is a white diamond-shaped tablet

600 microgram sublingual tablet is a white “D”-shaped tablet

800 microgram sublingual tablet is a white capsule-shaped tablet

Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Abstral Sublingual 100MG,   should only be administered to patients who are considered tolerant to their opioid therapy for persistent cancer pain. Patients can be considered opioid tolerant if they take at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

Method of administration:

Abstral Sublingual 100MG tabletter bør administreres direkte under tungen i den dypeste delen. Abstral sublingual tabletter bør ikke svelges, men tillatt å fullstendig løse opp i sublingual hulrom uten å tygge eller suge på. Pasienter bør rådes til ikke å spise eller drikke noe til den sublingual nettbrettet er helt oppløst.

In patients who have a dry mouth water may be used to moisten the buccal mucosa before taking Abstral.

Dose titration:

The object of dose titration is to identify an optimal maintenance dose for ongoing treatment of breakthrough pain episodes. This optimal dose should provide adequate analgesia with an acceptable level of adverse reactions.

The optimal dose of Abstral will be determined by upward titration, on an individual patient basis. Several doses are available for use during the dose titration phase. The initial dose of Abstral used should be 100 micrograms, titrating upwards as necessary through the range of available dosage strengths.

Patients should be carefully monitored until an optimal dose is reached.

Switching from other fentanyl containing products to Abstral must not occur at a 1:1 ratio because of different absorption profiles. If patients are switched from another fentanyl containing product, a new dose titration with Abstral is required.

The following dose regimen is recommended for titration, although in all cases the physician should take into account the clinical need of the patient, age and concomitant illness.

All patients must start therapy with a single 100 microgram sublingual tablet. If adequate analgesia is not obtained within 15-30 minutes of administration of a single sublingual tablet, a supplemental (second) 100 microgram sublingual tablet may be administered. If adequate analgesia is not obtained within 15-30 minutes of the first dose an increase in dose to the next highest tablet strength should be considered for the next episode of breakthrough pain (Refer to figure below).

Dose escalation should continue in a stepwise manner until adequate analgesia with tolerable adverse reactions is achieved. The dose strength for the supplemental (second) sublingual tablet should be increased from 100 to 200 micrograms at doses of 400 micrograms and higher. This is illustrated in the schedule below. No more than two (2) doses should be administered for a single episode of breakthrough pain during this titration phase.